Long-term survival after resolution of pulmonary metastasis in a patient with unresectable cervical esophageal carcinoma after nivolumab-induced immune-related adverse events
{{output}}
Nivolumab is a first-line treatment for unresectable esophageal cancer; however, immune-related adverse events (irAEs) can be severe. We report a rare case of long-term survival without chemotherapy after the resolution of lung metastases potentially triggered... ...
